Novel Therapeutics Emerging Technologies Industry Trends
I have managed pharmaceutical and biomedical research enterprises for over forty years, creating patented innovations in chemical biology. My research and expertise are in the fields of medicinal chemistry and all aspects of pre-clinical drug development, with a heavy emphasis on phenotypic studies and physiologically based PK/PD. I was trained both as a biologist and a chemist. In 2013, I left the executive rat race in the Kendall Square pharma Mecca (Cambridge, MA). Now, when not consulting to early stage companies or running portfolio reviews and due diligence, I spend my time analyzing and commenting on trends.
tags: Assay Technology Big Data Biologics Biopharma Policies, Regulations CRISPR Database Drug Targets High-Throughput Screening (HTS) Immunotherapy In Silico MedChem Small Molecules
Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.